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AF

:   atrial fibrillation
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:   amyotrophic lateral sclerosis

CPVT

:   catecholaminergic polymorphic ventricular tachycardia

I~Na~

:   Na^+^ current
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Na~v~

:   Na^+^ channel

nNa~v~

:   neuronal Na^+^ channel

NCX

:   Na^+^/Ca^2+^ exchange

RyR2

:   ryanodine receptor
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:   sarcoplasmic reticulum
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Clinical PerspectiveWhat Is New?Riluzole, a neuronal type Na^+^ channel blocker, was investigated in 2 retrospective amyotrophic lateral sclerosis cohorts.Patients treated with riluzole had significantly lowered incidence of arrhythmias, including new‐onset atrial fibrillation.What Are the Clinical Implications?The pharmacological class of neuronal‐type Na^+^ channel blockade may offer a unique mechanism to prevent arrhythmias including atrial fibrillation.

 {#jah35164-sec-0008}

Atrial arrhythmia, such as atrial fibrillation (AF), is a leading cause of morbidity and mortality in the United States.[1](#jah35164-bib-0001){ref-type="ref"} It is a common comorbidity associated with heart failure and its risk has been associated with "leaky" ryanodine receptor 2 (RyR2) Ca^2+^ release channels.[2](#jah35164-bib-0002){ref-type="ref"}, [3](#jah35164-bib-0003){ref-type="ref"}, [4](#jah35164-bib-0004){ref-type="ref"} The importance of leaky RyR2 to atrial arrhythmogenesis is particularly evident in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).[5](#jah35164-bib-0005){ref-type="ref"} In this pathology, mutations in RyR2 or in the sarcoplasmic reticulum (SR) Ca^2+^‐binding protein calsequestrin increase propensity for AF.[6](#jah35164-bib-0006){ref-type="ref"} Emerging evidence also suggests that the link between Ca^2+^ handling and atrial arrhythmias is in part modulated by Na^+^ influx.[7](#jah35164-bib-0007){ref-type="ref"}

The predominant Na^+^ channel (Na~v~) isoform found in the heart (Na~v~1.5) is decreased in cardiomyopathy, as well as in AF.[7](#jah35164-bib-0007){ref-type="ref"}, [8](#jah35164-bib-0008){ref-type="ref"} However, tetrodotoxin‐sensitive neuronal‐type Na^+^ channels (nNa~v~s) are upregulated in these pathologies resulting in enhanced persistent Na^+^ current (I~Na~).[7](#jah35164-bib-0007){ref-type="ref"}, [9](#jah35164-bib-0009){ref-type="ref"} The subcellular localization of different Na~V~ isoforms thus determines the location of late Na^+^ entry relative to Ca^2+^‐handling machinery. This, in turn, may determine whether nNa~v~‐mediated Na^+^/Ca^2+^ exchange (NCX) merely contributes to global cytosolic Ca^2+^ overload or acts directly to trigger abnormal Ca^2+^ release.[10](#jah35164-bib-0010){ref-type="ref"}, [11](#jah35164-bib-0011){ref-type="ref"}, [12](#jah35164-bib-0012){ref-type="ref"}

Ventricular proarrhythmia is an important limitation of current drug therapies used in AF.[13](#jah35164-bib-0013){ref-type="ref"}, [14](#jah35164-bib-0014){ref-type="ref"}, [15](#jah35164-bib-0015){ref-type="ref"} Thus, the identification of agents that safely and effectively prevent arrhythmogenic trigger in the atria is imperative. Riluzole, an nNa~v~ inhibitor used to manage amyotrophic lateral sclerosis (ALS),[16](#jah35164-bib-0016){ref-type="ref"} effectively suppresses triggered ventricular arrhythmias in multiple animal models.[10](#jah35164-bib-0010){ref-type="ref"}, [17](#jah35164-bib-0017){ref-type="ref"}, [18](#jah35164-bib-0018){ref-type="ref"}, [19](#jah35164-bib-0019){ref-type="ref"} Given its extensive safety profile,[20](#jah35164-bib-0020){ref-type="ref"} riluzole could potentially safely prevent AF. Here, we provide evidence from preclinical models and patients suggesting riluzole as a safe and effective treatment for atrial arrhythmias.

Methods {#jah35164-sec-0009}
=======

Expanded methods are available in Data [S1](#jah35164-sup-0001){ref-type="supplementary-material"}.

The preclinical and retrospective cohort data that support the findings of this study are available from the corresponding author and Dr Mark Munger (<mark.munger@hsc.utah.edu>), respectively, upon reasonable request.

Study Approval {#jah35164-sec-0010}
--------------

All animal procedures were approved by The Ohio State University and University of Michigan Institutional Animal Care and Use Committees and conformed to the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (publication No. 85‐23, revised 2011). The historical cohort was reviewed and approved as exempt following applicable guidelines involving the ethical treatment of human subjects by the University of Utah\'s institutional review board before the initiation of data collection. The University of Utah\'s institutional review board is fully accredited by the Human Research Protection Program.

Preclinical Evaluation of Antiarrhythmic Targeting of nNa~v~s {#jah35164-sec-0011}
-------------------------------------------------------------

Atrial cardiomyocytes, obtained from cardiac calsequestrin mutant (R33Q) wild‐type (WT) mice or failing canine hearts were enzymatically dissociated for patch‐clamp recordings, confocal immunolabeling, or Ca^2+^ imaging. A subset of mice was used to assess the role of nNa~v~s in an in vivo arrhythmia induction.

Clinical Evaluation of Antiarrhythmic Targeting of nNa~v~s {#jah35164-sec-0012}
----------------------------------------------------------

We conducted a retrospective cohort study of patients with ALS who were treated with riluzole (study group) versus no riluzole (control group) from the ALS Centre of the Azienda Ospedaliero, Universitaria di Modena, Modena, Italy, and the University of Utah, Salt Lake City, Utah. Data were collected through queries of structured data fields. Variables extracted from structured fields included demographic information (ie, age on the index date, sex, race, and body mass index), laboratory results, diagnostic tests and results, prescription records, and hospitalizations with cardiovascular encounter(s) including acute coronary syndrome, acute myocardial infarction, heart failure, and any arrhythmia including atrial flutter or fibrillation. Race and ethnicity were grouped into white, black, Hispanic, Asian, and other/unknown. Cardiovascular risk factors and specific medications for cardiovascular risk prevention and treatment were collected and identified. Distribution of the clinical and demographic characteristics of the study cohort were described among the overall cohort from both the Italian and US databases, and among riluzole versus no‐riluzole users. Baseline characteristics between the riluzole and no‐riluzole groups were compared using chi‐square test, and Fisher exact test if the number of patients having a specific clinical character was \<5. Cardiac pacemaker and implantable cardioverter‐defibrillator placement were collected, if applicable, and cardiac monitoring for AF was conducted based on patient presentation of symptoms.

The primary clinical end point was a composite of arrhythmia and AF. The time‐to‐end point from the first exposure to riluzole or earliest available date on or after the diagnosis of ALS, if no riluzole cohort, was projected using Kaplan--Meier curves where patients were censored when they encountered the end point or at the last follow‐up from each institution. The measure of treatment effect was hazard ratio (HR) and 95% CI estimate from Cox proportional hazard regression model under intention‐to‐treat principles (ie, post‐index date variables were not incorporated into the analysis such as medication adherence) where the effect measure was adjusted for the baseline characteristics that were marginally different (*P*\<0.1) between the riluzole and no‐riluzole groups. The analysis was performed for the overall cohort, then limited to the Utah cohort to qualitatively examine the influence of the heterogeneity across the Italy and US cohorts on the measure of treatment effect. All tests were 2‐tailed with an α of 0.05 for statistical significance. Data analysis was conducted with SAS version 9.4 (SAS Institute Inc).

Results {#jah35164-sec-0013}
=======

nNa~v~ Blockade Prevents Leaky RyR2‐Induced Aberrant Ca^2+^ Oscillations {#jah35164-sec-0014}
------------------------------------------------------------------------

We first determined whether nNa~v~ exerts a unique action on intracellular Ca^2+^ handling, which may contribute to atrial arrhythmia initiation. Exposure of calsequestrin‐associated CPVT atrial myocytes to isoproterenol (100 nmol/L) induced self‐sustaining, repetitive Ca^2+^ oscillations, consistent with previous findings.[6](#jah35164-bib-0006){ref-type="ref"} These oscillations were abolished by tetrodotoxin (100 nmol/L; Figure [1](#jah35164-fig-0001){ref-type="fig"}A). Further, tetrodotoxin prevented induction of repetitive Ca^2+^ oscillations by field stimulation in the presence of isoproterenol in nearly all cells tested (Figure [1](#jah35164-fig-0001){ref-type="fig"}A), despite increasing SR Ca^2+^ load (Figure [S1](#jah35164-sup-0001){ref-type="supplementary-material"}). However, field stimulation elicited Ca^2+^ oscillations in all cells upon washout of tetrodotoxin (Figure [1](#jah35164-fig-0001){ref-type="fig"}A).

![Inhibition of tetrodotoxin (TTX)‐sensitive neuronal Na~V~s (nNa~v~s) is sufficient to prevent induction of aberrant, repetitive Ca^2+^ oscillations in R33Q atrial myocytes.\
**A**, Representative examples of the line scan images and corresponding Ca^2+^ transients recorded in field‐stimulated R33Q atrial cardiomyocytes paced at 0.5 Hz and loaded with the Ca^2+^ indicator, Fluo‐3 AM. Cells were treated with isoproterenol (ISO, 100 nmol/L) and subsequently TTX (100 nmol/L; green arrow indicates time when TTX was added) was rapidly applied. β‐Adrenergic stimulation with ISO promoted aberrant, repetitive Ca^2+^ oscillations (median pacing frequency was 2 Hz with the range of 0.5 to 4 Hz), while TTX (100 nmol/L) significantly decreased their incidence. Ca^2+^ oscillations were induced after drug washout (red arrow; number of cells tested depicted under the corresponding bars, N=8 animals for ISO and ISO‐TTX, N=6 animals for ISO‐washout, respectively; \*\*\**P*\<0.0001 McNemar test for ISO vs ISO‐TTX, *P*\<0.0001 Fisher exact test for ISO‐TTX vs ISO‐washout). **B**, Treatment of ISO (100 nmol/L)‐exposed R33Q atrial myocytes with 10 μmol/L riluzole (Ril) significantly reduced the incidence of aberrant, repetitive Ca^2+^ oscillations, an effect that was washable (median pacing frequency was 2 Hz with the range of 0.5 to 7 Hz; number of cells tested depicted under the corresponding bars, N=10 animals for ISO and ISO‐Ril, N=8 animals for ISO‐washout, respectively; \*\*\**P*\<0.0001 McNemar test for ISO vs ISO‐Ril, *P*\<0.0001 Fisher exact test for ISO‐Ril vs ISO‐washout).](JAH3-9-e015119-g001){#jah35164-fig-0001}

Next, we compared tetrodotoxin with riluzole, an agent currently employed in the management of ALS.[21](#jah35164-bib-0021){ref-type="ref"} At the resting potential, riluzole has been shown to preferentially block tetrodotoxin‐sensitive nNa~v~s in dorsal root ganglion neurons.[16](#jah35164-bib-0016){ref-type="ref"} First, we examined the impact of riluzole on the tetrodotoxin‐sensitive component of I~Na~. Both 100 nmol/L tetrodotoxin and 10 μmol/L riluzole reduced peak I~Na~ density to similar degrees (peak I~Na~ at −35 mV of −36.4±3.7 pA/pF versus −25.8±4.4 and −28.1±3.0 pA/pF for control, riluzole and tetrodotoxin, respectively; *P*=0.0002 Kruskal--Wallis rank sum test; Figure [S2](#jah35164-sup-0001){ref-type="supplementary-material"}A). Both also shifted steady‐state inactivation of I~Na~ to more hyperpolarized potentials (V~1/2~ of −87.2±3.7 mV versus −98.1±3.0 and −95.9±3.2 mV for R33Q, riluzole and tetrodotoxin, respectively; *P*=0.0345 Kruskal--Wallis rank sum test; Figure [S2](#jah35164-sup-0001){ref-type="supplementary-material"}B). Importantly, riluzole, like tetrodotoxin, prevented aberrant Ca^2+^ oscillations (Figure [1](#jah35164-fig-0001){ref-type="fig"}B) and increased SR Ca^2+^ load (Figure [S1](#jah35164-sup-0001){ref-type="supplementary-material"}). These data point to the antiarrhythmic efficacy in CPVT of nNa~V~ inhibition by riluzole, likely via suppression of late I~Na~ induced by isoproterenol. Under control conditions, we did not observe significant differences in late I~Na~ between WT and CPVT (Figures [2](#jah35164-fig-0002){ref-type="fig"}B and [5](#jah35164-fig-0005){ref-type="fig"}A). Upon addition of isoproterenol (100 nmol/L), CPVT atrial myocytes evidenced an increase in late I~Na~ (Figure [2](#jah35164-fig-0002){ref-type="fig"}B). Both peak as well as late I~Na~ were reduced by riluzole (Figure [2](#jah35164-fig-0002){ref-type="fig"}). Taken together, these data support a role for nNa~v~ in arrhythmogenic Ca^2+^ release in CPVT atria.

![Effect of neuronal Nav (nNav) blockade with riluzole (Ril) on isoproterenol (ISO)‐promoted inward Na^+^ currents (I~Na~) in R33Q atrial myocytes.\
**A**, Representative I~Na~ (top) were elicited by a protocol presented in the inset before (black) or after addition of ISO (100 nmol/L; red) or ISO (100 nmol/L)+Ril (10 μmol/L; purple). (Bottom) Corresponding current‐voltage relationship from control, ISO, and ISO+Ril (n=10, 9, and 7 cells from 5, 6, and 5 mice, respectively). Addition of ISO+Ril reduced I~Na~ density relative to ISO alone (peak I~Na~ at −40 mV of −37.1±3.2 vs −22.4±3.9 pA/pF for ISO and ISO+Ril, respectively; *P*=0.0102 ANOVA, *P*=0.0418 for ISO vs ISO+Ril). **B**, Representative traces of persistent I~Na~ elicited using the protocol shown in the inset were recorded before (black) or after addition of ISO (100 nmol/L; red) or ISO+Ril (10 μmol/L; purple). ISO enhanced persistent I~Na~ in R33Q cardiomyocytes, while Ril suppressed β‐adrenergic--mediated increase in persistent I~Na~ (n=9, 8, and 8 cells from 3, 3, and 4 mice for R33Q, ISO, and ISO‐Ril, respectively; *P*\<0.0001 ANOVA, \*\*\**P*=0.0004 for persistent I~Na~ integral and \*\*\**P*\<0.0001 for normalized late I~Na~). Summary data are presented as persistent I~Na~ integral Amp‐ms/F (AmsF^−1^; left) or normalized late I~Na~ (%; right), which were measured by either integrating I~Na~ between 50 and 450 ms (left) or normalizing mean persistent INa recorded between 250 and 450 ms by peak current generated by a step to ‐40 mV.](JAH3-9-e015119-g002){#jah35164-fig-0002}

We also examined whether blockade of other Na~V~ isoforms and/or RyR2 in addition to tetrodotoxin‐sensitive Na~V~ isoforms confers additional benefit beyond that achieved with 100 nmol/L tetrodotoxin. To that end, we used R‐propafenone[22](#jah35164-bib-0022){ref-type="ref"}, [23](#jah35164-bib-0023){ref-type="ref"}, [24](#jah35164-bib-0024){ref-type="ref"}, [25](#jah35164-bib-0025){ref-type="ref"} (300 nmol/L) and ranolazine[26](#jah35164-bib-0026){ref-type="ref"}, [27](#jah35164-bib-0027){ref-type="ref"}, [28](#jah35164-bib-0028){ref-type="ref"}, [29](#jah35164-bib-0029){ref-type="ref"} (10 μmol/L) to assess their effect on cellular arrhythmia potential. At these concentrations, ranolazine and R‐propafenone achieved similar levels of peak I~Na~ reduction relative to riluzole (peak I~Na~ at −40 mV of −22.4±3.9 pA/pF versus −23.9±2.7 pA/pF and −23.3±1.5 pA/pF for isoproterenol+riluzole versus isoproterenol+ranolazine and isoproterenol+R‐propafenone, respectively; Figures [2](#jah35164-fig-0002){ref-type="fig"}A and [3](#jah35164-fig-0003){ref-type="fig"}A). Furthermore, both of these agents reduced induction of aberrant Ca^2+^ oscillations (Figure [3](#jah35164-fig-0003){ref-type="fig"}C and [3](#jah35164-fig-0003){ref-type="fig"}D). Notably, the extent of reduction in cellular arrhythmia propensity was proportional to the extent of late I~Na~ reduction achieved by these agents (Figure [3](#jah35164-fig-0003){ref-type="fig"}B), suggesting that nNav blockade is sufficient for the antiarrhythmic effect of Na~V~ blockers. Furthermore, the effects of these 2 compounds were, in part, washable (Figure [3](#jah35164-fig-0003){ref-type="fig"}C and [3](#jah35164-fig-0003){ref-type="fig"}D).

![The extent of late inward Na^+^ currents (I~Na~) inhibition corresponds to prevention of aberrant, repetitive Ca^2+^ oscillations in R33Q atrial myocytes.\
**A**, (Left) I~Na~ obtained by step protocol illustrated in 1‐second intervals. (Right) In isoproterenol (ISO; 100 nmol/L)‐treated R33Q atrial myocytes, addition of ranolazine (Ran; 10 μmol/L, blue trace and bar; n=5 from N=4 animals) or R‐propafenone (R‐prop; 300 nmol/L, orange trace and bar; n=4 from N=3 animals) significantly reduced peak I~Na~ (*P*=0.0016 ANOVA, \**P*=0.0418 for ISO vs ISO+Ran and \**P*=0.0246 for ISO vs ISO+R‐prop) relative to ISO alone (n=7 from N=5 animals). Notably, there was no difference in peak I~Na~ reduction between the groups. **B**, (Left) Representative persistent I~Na~ elicited using the protocol shown in the inset. (Right) ISO (100 nmol/L) increased persistent I~Na~, while Ran and R‐prop reduced it (n=13, 13, 7, and 7 cells from 6, 6, 6 and 4 mice for R33Q, ISO, ISO+Ran, and ISO+R‐prop, respectively; *P*\<0.0001 ANOVA, \*\*\**P*\<0.0001, \*\**P*=0.0082, and \**P*=0.0480). Notably, R‐prop reduced ISO‐induced persistent I~Na~ to a greater extent than Ran (*P*=0.0480). **C**, Treatment of ISO (100 nmol/L)‐exposed R33Q atrial myocytes with Ran (10 μmol/L) significantly reduced the incidence of aberrant, repetitive Ca^2+^ oscillations, which was washable (number of cells tested depicted under the corresponding bars, N=5 animals; \*\*\**P*=0.0009 McNemar test for ISO vs ISO‐Ran and for ISO‐Ran vs ISO‐washout). **D**, R‐prop abolished aberrant, repetitive Ca^2+^ oscillations, an effect that was only partially washable only after 10 minutes. (Number of cells tested depicted under the corresponding bars, N=4 animals; \*\*\**P*=0.0005 McNemar test for ISO vs ISO--R‐prop, \**P*=0.0455 for ISO--R‐propafenone vs ISO‐washout).](JAH3-9-e015119-g003){#jah35164-fig-0003}

Next, we confirmed the importance of NCX to the proarrhythmic process in this model.[6](#jah35164-bib-0006){ref-type="ref"}, [11](#jah35164-bib-0011){ref-type="ref"} Acute NCX inhibition (5 mmol/L NiCl~2~) abolished repetitive Ca^2+^ oscillations in all cells tested (Figure [S3](#jah35164-sup-0001){ref-type="supplementary-material"}A). Since we were unable to electrically stimulate cardiomyocytes in the presence of NiCl~2~, we repeated these experiments during NCX inhibition with SEA0400 (1 μmol/L). SEA0400 prevented induction of arrhythmogenic Ca^2+^ oscillations in over two thirds of cells tested (Figure [S3](#jah35164-sup-0001){ref-type="supplementary-material"}B).

nNa~v~s Closely Associate With Ca^2+^‐Handling Machinery {#jah35164-sec-0015}
--------------------------------------------------------

In order to examine close proximity of nNa~v~ with SR Ca^2+^‐release machinery, which may contribute to aberrant Ca^2+^ release through NCX in atrial myocytes, we performed confocal microscopy. This approach identified multiple nNa~v~ isoforms (Na~v~1.1, Na~v~1.3, and Na~v~1.6) localized near RyR2 and NCX in atrial myocytes from R33Q hearts (Figure [4](#jah35164-fig-0004){ref-type="fig"}A and [4](#jah35164-fig-0004){ref-type="fig"}B, top). Proximity ligation assays[10](#jah35164-bib-0010){ref-type="ref"} confirmed close association (within 40 nm)[30](#jah35164-bib-0030){ref-type="ref"} of all 3 nNa~v~ isoforms with RyR2 and NCX (Figure [4](#jah35164-fig-0004){ref-type="fig"} and [4](#jah35164-fig-0004){ref-type="fig"}B, bottom). These results place nNa~v~s near enough to leaky RyR2 to promote arrhythmias via aberrant NCX.

![Neuronal Na^+^ channel (nNa~V~) and ryanodine receptor 2 (RyR2) colocalize to the same discrete subcellular regions.\
Representative confocal micrographs of myocytes isolated from R33Q mice labeled for (**A**) RyR2 (red) and (**B**) Na^+^/Ca^2+^ exchange (NCX; red) with various Na^+^ channel (Na~v~) isoforms (Na~v~1.x, green). These often resulted in an overlap between the immunofluorescent signals (yellow) when overlaid. (Right) Close‐up views of regions highlighted by dashed white boxes. (Bottom) Representative fluorescent proximity ligation assay signal for RyR2 (A) and NCX (B) with different nNa~v~ isoforms (Na~V~1.x).](JAH3-9-e015119-g004){#jah35164-fig-0004}

Augmentation of nNa~v~ Activity is Proarrhythmic {#jah35164-sec-0016}
------------------------------------------------

Next, we examined whether augmented nNa~v~--mediated Na^+^ influx is sufficient to induce arrhythmogenic Ca^2+^ oscillations. Exposing WT myocytes to isoproterenol alone was insufficient to elicit Ca^2+^ oscillations. However, persistent I~Na~ induced by nNa~v~ augmentation (β‐pompilidotoxin, 40 μmol/L; Figure [5](#jah35164-fig-0005){ref-type="fig"}A)[10](#jah35164-bib-0010){ref-type="ref"}, [31](#jah35164-bib-0031){ref-type="ref"} promoted arrhythmogenic Ca^2+^ oscillations in WT cardiomyocytes exposed to isoproterenol (Figure [5](#jah35164-fig-0005){ref-type="fig"}B). This aberrant Ca^2+^ release resulted in a reduced SR Ca^2+^ load (Figure [S4](#jah35164-sup-0001){ref-type="supplementary-material"}). Taken together, these data are consistent with the notion that enhanced nNa~v~‐mediated Na^+^ influx is necessary as well as sufficient to produce proarrhythmic Ca^2+^ oscillations in WT atrial myocytes.

![Augmentation of tetrodotoxin (TTX)‐sensitive neuronal Nav (nNav) is sufficient to initiate aberrant, repetitive Ca^2+^ oscillations in wild‐type (WT) atrial myocytes.\
**A**, Representative traces of persistent inward Na^+^ currents (I~Na~) recorded in WT atrial cardiomyocytes before (black) and after (red) exposure to β‐pompilidotoxin (β‐PMTX; 40 μmol/L). β‐PMTX increased persistent I~Na~ relative to control (n=11 and 10 cells from 3 mice, respectively; \*\*\**P*\<0.0001 Wilcoxon rank sum test). **B**, (Left) Representative line scan images obtained from WT atrial cardiomyocytes exposed to isoproterenol (ISO; 100 nmol/L) and paced at 1 Hz. (Right) Rapid application of β‐PMTX (40 μmol/L) induced aberrant, repetitive Ca^2+^ oscillations. (Median pacing frequency was 0.5 Hz with the range of 0.5 to 2 Hz; number of cells tested depicted under the corresponding bars, from N=3 mice; \*\*\**P*\<0.0001 Fisher exact test for ISO vs ISO--β‐PMTX, \*\*\**P*\<0.0001 Fisher exact test for ISO--β‐PMTX vs ISO‐washout).](JAH3-9-e015119-g005){#jah35164-fig-0005}

nNa~v~s Modulate Atrial Arrhythmias in Mice {#jah35164-sec-0017}
-------------------------------------------

To determine the effects of nNa~v~ inhibition on atrial arrhythmias in mice with leaky RyR2,[32](#jah35164-bib-0032){ref-type="ref"} we treated them with riluzole (15 mg/kg IP).[33](#jah35164-bib-0033){ref-type="ref"} Atrial arrhythmia inducibility by atrial‐burst pacing was reduced by half following riluzole treatment (Figure [6](#jah35164-fig-0006){ref-type="fig"}A). In contrast, augmentation of nNa~v~‐mediated Na^+^ influx by β‐pompilidotoxin (40 mg/kg IP) promoted atrial arrhythmias in WT mice: caffeine and epinephrine challenge induced atrial arrhythmias in 58% (7 of 12) of β‐pompilidotoxin--treated mice, compared with 15% (2 of 13) of untreated controls (Figure [6](#jah35164-fig-0006){ref-type="fig"}B). Taken together, these data suggest that perturbing local Na^+^‐Ca^2+^ crosstalk via modulation of nNa~v~ potently regulates atrial arrhythmia risk in vivo.

![Modulation of tetrodotoxin (TTX)‐sensitive neuronal Nav (nNav) channel correspondingly modulates atrial arrhythmias in mice.\
**A**, Simultaneous surface ECG (lead II) and intracardiac atrial electrograms with frequent, rapid P waves and irregular RR intervals suggestive of atrial arrhythmia such as atrial flutter and atrial fibrillation in R33Q mice after burst pacing. Pretreatment with riluzole (Ril; 15 mg/kg IP), targeting plasma concentrations of \~10 μmol/L,[33](#jah35164-bib-0033){ref-type="ref"} reduced the atrial arrhythmia inducibility (n=7 mice; \*\**P*=0.0160 Wilcoxon signed rank test). **B**, Representative surface ECG recordings of wild‐type (WT) mice treated (top, red ECG) or untreated (bottom, black ECG) with β‐pompilidotoxin (β‐PMTX; 40 mg/kg IP) and exposed to catecholamine challenge with epinephrine (Epi, 1.5 mg/kg) and caffeine (Caff, 120 mg/kg). Since increased heart rate has been linked to reduced arrhythmia inducibility in calsequestrin null mice, and WT mice show higher heart rate relative to calsequestrin null mice,[32](#jah35164-bib-0032){ref-type="ref"} all WT animals were pretreated with ivabradine (3 mg/kg) for 10 minutes before any intervention. Epi+Caff challenge during β‐PMTX exposure precipitated repetitive P waves and irregular RR intervals suggestive of atrial arrhythmia in over 50% of WT mice, which is a 3‐fold increase relative to β‐PMTX--untreated mice (number of mice tested and those positive for atrial arrhythmias depicted under the corresponding bars; \**P*=0.0410 Fisher exact test).](JAH3-9-e015119-g006){#jah35164-fig-0006}

Targeting nNa~v~s With Riluzole Prevents Arrhythmias in a Canine Cardiomyopathy Model {#jah35164-sec-0018}
-------------------------------------------------------------------------------------

Next, we examined the contribution of nNa~v~s to atrial arrhythmogenesis in a clinically relevant chronic tachypacing‐induced canine cardiomyopathy model (4 months of tachypacing).[4](#jah35164-bib-0004){ref-type="ref"} This model allowed us to test the relevance of nNa~v~ blockade with riluzole in a much more complex pathology that goes beyond leaky RyR2. Riluzole (10 μmol/L) reduced the integral of persistent I~Na~ in the presence of isoproterenol (100 nmol/L) in nonfailing atria by 66±4%. This is consistent with the previous observation that about half of late I~Na~ in nonfailing canine ventricles is carried by tetrodotoxin‐sensitive nNa~v~s.[34](#jah35164-bib-0034){ref-type="ref"} Atrial myocytes isolated from cardiomyopathic canines evidenced enhanced persistent I~Na~ at baseline, relative to controls (Figure [7](#jah35164-fig-0007){ref-type="fig"}A and [7](#jah35164-fig-0007){ref-type="fig"}B). In contrast to controls, isoproterenol (100 nmol/L) did not further enhance persistent I~Na~ in failing atrial cells (Figure [7](#jah35164-fig-0007){ref-type="fig"}A and [7](#jah35164-fig-0007){ref-type="fig"}B). In the context of increased post‐translational modification of Ca^2+^ cycling proteins in this model,[4](#jah35164-bib-0004){ref-type="ref"} these results may point to increased post‐translational modification of Na~v~s at baseline in failing hearts. Concurrently, proximity ligation assay revealed reduced incidence of Na~V~1.1 and Na~V~1.3 localizing in proximity to RyR2, while Na~V~1.6 localization in proximity to both RyR2 and NCX was significantly increased (Figure [S5](#jah35164-sup-0001){ref-type="supplementary-material"}). Importantly, riluzole (10 μmol/L) reduced the integral of persistent I~Na~ in failing myocytes to the same level as in nonfailing atria (−67±9 versus −74±13  Amp.ms/F for failing and nonfailing atria, respectively; Figure [7](#jah35164-fig-0007){ref-type="fig"}A and [7](#jah35164-fig-0007){ref-type="fig"}B). Notably, enhanced persistent I~Na~ integral in failing atrial myocytes translated into aberrant Ca^2+^ cycling: all isoproterenol‐treated (100 nmol/L) failing atrial myocytes studied evidenced frequent, self‐sustaining Ca^2+^ oscillations (Figure [7](#jah35164-fig-0007){ref-type="fig"}C and [7](#jah35164-fig-0007){ref-type="fig"}D). Riluzole (10 μmol/L) significantly reduced these events, an effect that was reversed upon washout (Figure [7](#jah35164-fig-0007){ref-type="fig"}C and [7](#jah35164-fig-0007){ref-type="fig"}D). Taken together, these data suggest the translatability of targeting nNa~v~s with riluzole in complex pathologies.

![Riluzole (Ril) reduces enhanced, persistent inward Na^+^ currents (I~Na~) and prevents induction of aberrant, repetitive Ca^2+^ oscillations in canine heart failure (HF) atrial myocytes.\
**A**, Representative traces of persistent I~Na~ integral elicited using the protocol shown in the inset. Recordings were made in control (top) and failing (bottom) atrial myocytes before (black) and after exposure to isoproterenol (ISO; 100 nmol/L, red) and after treatment with Ril (10 μmol/L, purple). At baseline, atrial cardiomyocytes from failing hearts showed a larger persistent I~Na~ integral relative to control. ISO (100 nmol/L) enhanced persistent I~Na~ only in control cardiomyocytes. Ril reduced persistent I~Na~ integral in both control and failing atrial myocytes. **B**, Summary data are presented as persistent I~Na~ integral Amp‐ms/F (AmsF^−1^), which was measured by integrating I~Na~ between 50 and 450 ms (n=7 and 9 cells from 5 control and 3 failing dogs; *P*\<0.0001 Kruskal--Wallis test; \**P*=0.0126 for control vs ISO, \**P*=0.0209 for control vs ISO+Ril, \**P*=0.0268 for control‐ISO vs HF‐ISO, \*\*\**P*\<0.0001). **C**, Representative examples of the line‐scan images and corresponding Ca^2+^ transients recorded in canine HF atrial cardiomyocytes loaded with Ca^2+^ indicator, Fluo‐3 AM, and paced at 0.5 Hz with field stimulation. (Top) Cells were treated with ISO (100 nmol/L) and subsequently Ril (10 μmol/L; purple bar indicates time when Ril was added) was rapidly applied. (Bottom) Resumption of field stimulation failed to induce Ca^2+^ oscillations during concomitant exposure to ISO and Ril; however, washout of Ril resulted in their reinitiation. **D**, Ril significantly reduced the incidence of aberrant, repetitive Ca^2+^ oscillations, an effect that was washable (median pacing frequency was 0.5 Hz with the range of 0.5 to 1 Hz; number of cells tested depicted under the corresponding bars, N=3 animals for ISO and ISO‐Ril, N=2 animals for ISO‐washout, respectively; \*\**P*=0.0009 McNemar test for ISO vs ISO‐Ril, *P*\<0.0001 Fisher exact test for ISO‐Ril vs ISO‐washout incidence; \*\*\**P*=0.0005 Friedman rank sum test for Ca^2+^ oscillations frequency).](JAH3-9-e015119-g007){#jah35164-fig-0007}

Targeting nNa~v~s With Riluzole Controls New‐Onset AF in Patients With ALS {#jah35164-sec-0019}
--------------------------------------------------------------------------

Based on the results from the canine model, we examined the effect of riluzole on atrial arrhythmias in human patients via a retrospective cohort study. The research cohort consisted of 184 Italian patients prescribed riluzole, 314 US patients prescribed riluzole, and 735 riluzole‐free patients from the United States ([Table](#jah35164-tbl-0001){ref-type="table"}). Compared with the no‐riluzole patients, patients taking riluzole were age equivalent and had significantly more cardiovascular risk factors, more active disease, and more recorded cardiovascular events. In addition, the riluzole cohort were prescribed significantly more cardiovascular risk prevention and treatment medications, including β‐adrenergic blockers, Ca^2+^ channel blockers, aspirin, angiotensin system antagonists, and digitalis. The trends were consistent from both overall and US cohort analyses.

###### 

Baseline Characteristics

                          Riluzole, %   No Riluzole, %   Riluzole vs No Riluzole *P* Value              
  ----------------------- ------------- ---------------- ----------------------------------- ---------- ----------
  Age ≥65 y               44.6          40.4             43.7                                0.7475     0.3331
  Concurrent conditions                                                                                 
  Hypertension            25.5          14.0             7.2                                 \<0.0001   0.0005
  Hyperlipidemia          12.1          6.4              2.9                                 \<0.0001   0.0072
  Diabetes mellitus       7.8           7.0              5.0                                 0.0481     0.2042
  AMI or ACS              3.0           0.0              0.8                                 0.0036     0.1084
  Active smoking          15.1          2.2              0.0                                 \<0.0001   \<0.0001
  CAD                     9.2           1.6              1.2                                 \<0.0001   0.6344
  HF                      7.6           0.3              0.8                                 \<0.0001   0.3644
  Stroke                  3.4           0.0              0.0                                 \<0.0001   n/a
  Current medication                                                                                    
  β‐Blocker               6.6           0.3              0.0                                 \<0.0001   0.1258
  CCB                     5.6           0.0              0.0                                 \<0.0001   n/a
  ASA                     20.0          15.6             5.7                                 \<0.0001   \<0.0001
  Statins                 12.8          10.8             3.0                                 \<0.0001   \<0.0001
  ACEI or ARB             20.8          11.1             2.3                                 \<0.0001   \<0.0001
  Digitalis               0.8           0.0              0.0                                 0.0146     n/a

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetyl salicylic acid (aspirin); CAD, coronary artery disease (other than acute myocardial infarction \[AMI\] or acute coronary syndrome \[ACS\]); CCB, calcium channel blocker; HF, heart failure; and n/a, not applicable.

Patients with ALS treated with riluzole had significantly fewer overall cardiac arrhythmias. Five of 498 patients taking riluzole recorded tachyarrhythmia events versus 31 end points of 735 from the no‐riluzole cohort over the maximum follow‐up of 12 years, which resulted in the crude and adjusted HR of 0.28 (95% CI, 0.11--0.73; *P*=0.0088) and 0.25 (95% CI, 0.07--0.85; *P*=0.0272), respectively. The respective estimates when the analysis was limited to the US cohort were 0.25 (95% CI, 0.08--0.81; *P*=0.0210) and 0.21 (95% CI, 0.06--0.72; *P*=0.0129). The majority of arrhythmic events were distributed equivalently between supraventricular and ventricular tachycardia. The Kaplan--Meier curves of the arrhythmia events are presented in Figure [8](#jah35164-fig-0008){ref-type="fig"}, which reveals that arrhythmia events were reduced early and primarily throughout the first 2 years after riluzole prescribing. The majority of patients taking riluzole who recorded a tachyarrhythmia did not have cardiovascular disease. The rate of AF was lower in the rilozule group relative to the no‐riluzole group (*P*=0.0492). Specifically, AF occurred in 22 patients with ALS: 13 from Italy and 9 from the United States. One AF event was recorded after the riluzole prescription versus 9 events from the no‐riluzole cohort. Most patients who encountered AF had underlying cardiovascular disease (77%), with the majority treated with an angiotensin system antagonist; however, only 3 were treated with a β‐adrenergic blocker.

![Riluzole prevents cardiac arrhythmias in patients with amyotrophic lateral sclerosis (ALS).\
Two retrospective cohorts of ALS one exposed to riluzole vs no riluzole (controls), were compared by Cox proportional hazard models. The time‐to‐first composite arrhythmic events was analyzed using Kaplan--Meier production limit estimator. **A**, Overall cohort, (**B**) US cohort. HR indicates hazard ratio.](JAH3-9-e015119-g008){#jah35164-fig-0008}

Riluzole safety was determined during the study period by recording any abnormal neutrophil count, or transaminase level (ie, alanine aminotransferase/serum glutamic pyruvic transaminase, aspartate aminotransferase/serum glutamic oxaloacetic transaminase, bilirubin, or gamma‐glutamyl transferase levels). There was no record of any abnormal laboratory value in the study cohort.

Discussion {#jah35164-sec-0020}
==========

AF is the most common sustained cardiac arrhythmia.[35](#jah35164-bib-0035){ref-type="ref"} It is postulated that early use of rhythm control strategies may prevent arrhythmia progression.[36](#jah35164-bib-0036){ref-type="ref"} Current antiarrhythmic drugs such as flecainide or amiodarone are moderately beneficial in restoration and maintenance of sinus rhythm but produce serious adverse effects such as ventricular tachycardia, negative inotropy, and extracardiac toxicity.[37](#jah35164-bib-0037){ref-type="ref"}, [38](#jah35164-bib-0038){ref-type="ref"} Therefore, there is a need for an effective and safe alternative to current antiarrhythmic therapy for AF. In this study, we have examined a nNa~v~‐mediated mechanism for atrial arrhythmias in various preclinical models. These studies identify nNa~v~s as a druggable target for safe and effective atrial arrhythmia prevention. To translate these results into a real‐world setting, we undertook a retrospective cohort study of patients with ALS. Riluzole‐treated patients with ALS had fewer AF and ventricular arrhythmias than those undergoing conventional ALS therapy without riluzole. Taken together, these findings suggest that riluzole merits serious consideration as treatment for atrial arrhythmias.

Role of nNa~v~s in Atrial Arrhythmias {#jah35164-sec-0021}
-------------------------------------

Here, we demonstrate for the first time that nNa~V~s play a key role in the development of atrial arrhythmias in the presence of genetic (murine‐CPVT; Figure [1](#jah35164-fig-0001){ref-type="fig"}) or acquired (canine‐heart failure; Figure [7](#jah35164-fig-0007){ref-type="fig"}) Ca^2+^ handling dysfunction.[6](#jah35164-bib-0006){ref-type="ref"}, [39](#jah35164-bib-0039){ref-type="ref"} nNa~v~ blockade effectively suppressed atrial arrhythmias on the cellular level as well as in vivo (Figure [6](#jah35164-fig-0006){ref-type="fig"}). Contrariwise, acute experimental augmentation of nNa~v~ function was sufficient to precipitate cellular arrhythmias in healthy atrial myocytes (Figure [5](#jah35164-fig-0005){ref-type="fig"}). Further, augmentation of nNa~v~ activity reduced SR Ca^2+^ load (Figure [S4](#jah35164-sup-0001){ref-type="supplementary-material"}), while inhibition of these channels had the opposite effect (Figure [S1](#jah35164-sup-0001){ref-type="supplementary-material"}). This argues against global SR Ca^2+^ overload being the mechanism underlying the observed arrhythmias. Of note, blockade of other Na~V~ isoforms, including Na~V~1.5, with R‐propafenone[22](#jah35164-bib-0022){ref-type="ref"}, [23](#jah35164-bib-0023){ref-type="ref"}, [24](#jah35164-bib-0024){ref-type="ref"}, [25](#jah35164-bib-0025){ref-type="ref"} or ranolazine[26](#jah35164-bib-0026){ref-type="ref"}, [27](#jah35164-bib-0027){ref-type="ref"}, [28](#jah35164-bib-0028){ref-type="ref"}, [29](#jah35164-bib-0029){ref-type="ref"} in addition to nNa~V~s did not confer any apparent additional benefit beyond that achieved with 100 nmol/L of tetrodotoxin. This suggests that blockade of nNa~V~s is an important component of the antiarrhythmic mechanism of Na~V~ blockers.

Our structural results point to the close proximity of nNa~v~s to Ca^2+^‐handling machinery (RyR2 and NCX) as a potential factor underlying their privileged role in arrhythmogenesis (Figure [4](#jah35164-fig-0004){ref-type="fig"} and Figure [S5](#jah35164-sup-0001){ref-type="supplementary-material"}). In light of these findings, recent observations in patients with AF, which have revealed a reduction in Na~v~1.5 and upregulation of nNa~V~s,[7](#jah35164-bib-0007){ref-type="ref"} take on interesting implications. Mainly, remodeling within Na^+^/Ca^2+^ nanodomain, composed of nNa~V~s and Ca^2+^‐handling machinery (Figure [S5](#jah35164-sup-0001){ref-type="supplementary-material"}), may potentially compensate for failing excitation‐contraction coupling. Inversely, the late I~Na~ carried by these channels (Figure [7](#jah35164-fig-0007){ref-type="fig"}A and [7](#jah35164-fig-0007){ref-type="fig"}B) and the consequent NCX, can facilitate aberrant Ca^2+^ release through sensitized leaky RyR2 (Figure [7](#jah35164-fig-0007){ref-type="fig"}C and [7](#jah35164-fig-0007){ref-type="fig"}D).[40](#jah35164-bib-0040){ref-type="ref"}, [41](#jah35164-bib-0041){ref-type="ref"} This is in line with other reports of increased nNa~V~ and enhanced late I~Na~ in failing rat, canine, and human hearts.[7](#jah35164-bib-0007){ref-type="ref"}, [9](#jah35164-bib-0009){ref-type="ref"}, [42](#jah35164-bib-0042){ref-type="ref"} Hence, as proposed by our study, nNa~v~ blockade can be an effective antiarrhythmic strategy independent of remodeling within Na^+^/Ca^2+^ nanodomain or the pathogenesis of leaky RyR2.[7](#jah35164-bib-0007){ref-type="ref"}, [10](#jah35164-bib-0010){ref-type="ref"}, [17](#jah35164-bib-0017){ref-type="ref"}, [18](#jah35164-bib-0018){ref-type="ref"}, [43](#jah35164-bib-0043){ref-type="ref"} Furthermore, since ranolazine has been previously demonstrated to substantially affect multiple tetrodotoxin‐sensitive and ‐resistant Na~V~ isoforms (Na~V~1.1, Na~V~1.4, Na~V~1.5, Na~V~1.7, and Na~V~1.8)[26](#jah35164-bib-0026){ref-type="ref"}, [27](#jah35164-bib-0027){ref-type="ref"}, [28](#jah35164-bib-0028){ref-type="ref"}, [29](#jah35164-bib-0029){ref-type="ref"} at concentrations that are achieved therapeutically (\<10 μmol/L), tetrodotoxin‐sensitive nNa~V~ blockade may, in part, be an explanation for the effectiveness of ranolazine in reducing late I~Na~ in failing human atria.[7](#jah35164-bib-0007){ref-type="ref"} However, despite our study pointing to nNa~v~s as antiarrhythmia targets, future research will need to determine the specific Na~v~ isoform, or the combination thereof, necessary for the antiarrhythmic effect of riluzole and other Na~V~ blockers, such as ranolazine. Taken together, these results indicate a direct role for nNa~V~‐mediated Na^+^ influx in arrhythmia initiation, rather than it acting simply as a compounding factor.

Noteworthy, riluzole reduced persistent I~Na~ integral in nonfailing atria by 66±4%. This is consistent with previous observations that about half of late I~Na~ in canine ventricles is comprised of tetrodotoxin‐sensitive nNa~v~s.[34](#jah35164-bib-0034){ref-type="ref"} Furthermore, riluzole reduced persistent I~Na~ by similar absolute extents in both failing and nonfailing atrial myocytes. This corresponded to a greater proportional impact on persistent I~Na~ integral in failing myocytes (78±3%) versus nonfailing myocytes (66±4%) as a result of enhanced persistent I~Na~ in failing atria. Together, these data indicate a role for nNa~V~ remodeling within Ca^2+^‐handling nanodomains and increased post‐translational modification of Na~V~s in failing atria. This notion is consistent with findings in atria from patients with chronic AF, where an increase in nNa~V~ isoforms accounted for increased late I~Na~ in AF.[7](#jah35164-bib-0007){ref-type="ref"} However, despite the aforementioned studies providing a parallel to our results, we cannot rule out the potential involvement of Na~V~1.5 in AF nor potential Na~V~1.5 inhibition by riluzole to the drug\'s antiarrhythmic mechanism.

Riluzole‐Treated Human Patients are Protected From AF {#jah35164-sec-0022}
-----------------------------------------------------

Whereas both tetrodotoxin and riluzole effectively suppressed atrial arrhythmias in animal models, concerns over toxicity render tetrodotoxin an untenable clinical option. In contrast, riluzole has a proven safety record as a treatment for ALS. In line with this, our data also suggest that riluzole was well tolerated. Hence, in our retrospective cohort study of arrhythmia risk among patients with ALS, riluzole‐treated patients with ALS had both fewer AF and ventricular tachycardia diagnoses compared with nontreated patients (Figure [8](#jah35164-fig-0008){ref-type="fig"}). To our knowledge, this is the first evidence to show that riluzole may have antiarrhythmic properties in humans. However, because of the nonrandomized nature of this study, further controlled studies are necessary to confirm and extend this finding. Given that ventricular proarrhythmia is a critical limitation of current AF drug therapies,[13](#jah35164-bib-0013){ref-type="ref"}, [14](#jah35164-bib-0014){ref-type="ref"}, [15](#jah35164-bib-0015){ref-type="ref"} riluzole and potentially other nNa~v~ inhibitors may provide an urgently needed safe alternative.

Limitations {#jah35164-sec-0023}
-----------

A major limitation of small animal models is the translatability of findings into clinically relevant models of human disease. This factor is mitigated by our data demonstrating the antiarrhythmic efficacy of riluzole in a chronic tachypacing‐induced canine cardiomyopathy model. Riluzole can activate small‐conductance Ca^2+^‐activated K^+^ channels,[44](#jah35164-bib-0044){ref-type="ref"} which are upregulated in heart failure.[45](#jah35164-bib-0045){ref-type="ref"} While the possible contribution of this effect to riluzole\'s antiarrhythmic mechanism is not clear, our results with other Na~V~ inhibitors suggest that it is not necessary. Whether small‐conductance Ca^2+^‐activated K^+^ channel activation contributes to riluzole\'s antiarrhythmic effect will be an interesting subject for future study. Na^+^ channel blockers such as flecainide, R‐propafenone, or ranolazine can block RyR2, mitigating the impact of leaky RyR2.[25](#jah35164-bib-0025){ref-type="ref"}, [29](#jah35164-bib-0029){ref-type="ref"}, [46](#jah35164-bib-0046){ref-type="ref"} However, riluzole (10 μmol/L) did not affect Ca^2+^ sparks in permeabilized ventricular cardiomyocytes, a surrogate for RyR2 function.[17](#jah35164-bib-0017){ref-type="ref"} Even so, this mechanism merits further study. It is important to note that our retrospective cohort study of patients with ALS helps translate findings from animal models to humans. However, the study\'s observational and nonrandomized nature offers limited insight into the causality of observed effects. This limitation was mitigated, in part, by adjusting outcomes for baseline characteristics. Finally, outcomes were retrospectively obtained and were only available from existing data; therefore, we were not able to include any arrhythmia observations outside of the databases. Since other studies demonstrated similar incidence of arrhythmias,[47](#jah35164-bib-0047){ref-type="ref"} and valid results despite a similar limitation, we do not believe there would be differential ascertainment between the 2 cohorts.[48](#jah35164-bib-0048){ref-type="ref"} However, because of the unique character of the population (ie, ALS), further controlled studies are necessary to confirm and extend our findings.

Conclusions {#jah35164-sec-0024}
===========

We used experimental and preclinical animal models to delineate a mechanistically driven therapeutic strategy for atrial arrhythmias and provide evidence for its translational potential from a community‐based retrospective cohort. Specifically, we identify a nanodomain rich in nNa~V~s and Ca^2+^‐handling machinery (NCX and RyR2) that forms the basis of aberrant, self‐sustained Ca^2+^ release, resulting in atrial arrhythmias in vivo. Importantly, inhibition of nNa~v~s with riluzole demonstrates efficacy in preventing atrial arrhythmias in both animal models and human patients. Thus, riluzole has the potential to be repurposed as a therapy for preventing AF.
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